These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 874961)

  • 1. Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.
    Giraldi T; Nisi C; Connors TA; Goddard PM
    J Med Chem; 1977 Jun; 20(6):850-3. PubMed ID: 874961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and antitumor activity of derivatives of 1-phenyl-3,3-dimethyltriazene.
    Lin YT; Loo TL
    J Med Chem; 1972 Feb; 15(2):201-3. PubMed ID: 5008242
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis and antitumor activity of hydrosoluble analogs of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt.
    Varnavas A; Nisi C; Lassiani L; Sava G; Perissin L; Boccù E
    Arzneimittelforschung; 1991 Nov; 41(11):1168-72. PubMed ID: 1810263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
    Wilman DE; Goddard PM
    J Med Chem; 1980 Sep; 23(9):1052-4. PubMed ID: 7411549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
    Wilman DE; Cox PJ; Goddard PM; Hart LI; Merai K; Newell DR
    J Med Chem; 1984 Jul; 27(7):870-4. PubMed ID: 6737430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the antileukemic effects of 1-p-carboxamidophenyl-3,3-dimethyltriazene and its in vitro metabolites.
    Sava G; Giraldi T; Lassiani L; Nisi C; Farmer PB
    Biochem Pharmacol; 1982 Nov; 31(22):3629-34. PubMed ID: 7181944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the mode of action of antitumor triazenes and triazines. 6. 1-Aryl-3-(hydroxymethyl)-3-methyltriazenes: synthesis, chemistry, and antitumor properties.
    Vaughan K; Tang Y; Llanos G; Horton JK; Simmonds RJ; Hickman JA; Stevens MF
    J Med Chem; 1984 Mar; 27(3):357-63. PubMed ID: 6699881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional-group modifications of dextran for linkage to a diazonium group. A potential vehicle for tumour targeting of antineoplastic triazenes.
    Baki AV; Vaughan K
    Carbohydr Res; 1982 Jul; 105(1):57-68. PubMed ID: 6180830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the mode of action of antitumour triazenes and triazines--IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethyltriazene.
    Farina P; Gescher A; Hickman JA; Horton JK; D'Incalci M; Ross D; Stevens MF; Torti L
    Biochem Pharmacol; 1982 May; 31(10):1887-92. PubMed ID: 7104021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour inhibitory triazenes: structural requirements for an active metabolite.
    Connors TA; Goddard PM; Merai K; Ross WC; Wilman DE
    Biochem Pharmacol; 1976 Feb; 25(3):241-6. PubMed ID: 1267820
    [No Abstract]   [Full Text] [Related]  

  • 11. Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC.
    Cameron LM; LaFrance RJ; Hemens CM; Vaughan K; Rajaraman R; Chubb DC; Goddard PM
    Anticancer Drug Des; 1985 Oct; 1(1):27-36. PubMed ID: 3870878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,3-Dialkyl-3-acyltriazenes, a novel class of antineoplastic alkylating agents.
    Smith RH; Scudiero DA; Michejda CJ
    J Med Chem; 1990 Sep; 33(9):2579-83. PubMed ID: 2391696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimetastatic action of some triazene derivatives against the Lewis lung carcinoma in mice.
    Giraldi T; Houghton PJ; Taylor DM; Nisi C
    Cancer Treat Rep; 1978 May; 62(5):721-5. PubMed ID: 657157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of hydrazones and adducts between aromatic aldehydes and p-(3,3-dimethyl-1-triazeno)benzoic acid hydrazide.
    Giraldi T; Goddard PM; Nisi C; Sigon F
    J Pharm Sci; 1980 Jan; 69(1):97-8. PubMed ID: 7354457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
    Lin AJ; Loo TL
    J Med Chem; 1978 Mar; 21(3):268-72. PubMed ID: 628002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents.
    Horspool KR; Stevens MF; Newton CG; Lunt E; Walsh RJ; Pedgrift BL; Baig GU; Lavelle F; Fizames C
    J Med Chem; 1990 May; 33(5):1393-9. PubMed ID: 2329560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes.
    Gescher A; Hickman JA; Simmonds RJ; Stevens MF; Vaughan K
    Biochem Pharmacol; 1981 Jan; 30(1):89-93. PubMed ID: 7213416
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of cluster analysis in the development of structure-activity relations for antitumor triazenes.
    Dunn WJ; Greenberg MJ; Callejas SS
    J Med Chem; 1976 Nov; 19(11):1299-301. PubMed ID: 1003406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and cytotoxic effects of hydroxymethyl-3-pyridyl- and 2-chloro-5-pyridyltriazene derivatives.
    Grancharov KC; Koch M; Volm M; Kolar GF
    Cancer Lett; 1988 Aug; 41(3):271-9. PubMed ID: 3409206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
    Hatheway GJ; Hansch C; Kim KH; Milstein SR; Schmidt CL; Smith RN; Quinn FR
    J Med Chem; 1978 Jun; 21(6):563-74. PubMed ID: 671453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.